Department of Clinical Biochemistry, Manchester Royal Infirmary, Manchester, U.K.
Department of Postgraduate Studies and Research, Royal College of Surgeons in Ireland, Medical University of Bahrain, Busaiteen, Bahrain.
Diabetes Care. 2022 Feb 1;45(2):267-272. doi: 10.2337/dc21-2279.
The measurement of blood ketones in preference to urine ketones has become a well-established tool in the diagnosis and management of diabetic ketoacidosis (DKA). However, there remains considerable disparity between diabetes guidelines regarding if, how, and when this test should be used. While recent guidelines now mainly emphasize blood measurement, several issues nonetheless remain. Many laboratories still measure blood ketones using a semiquantitative test that does not measure the predominant ketone, β-hydroxybutyrate (BOHB), which may hinder patient management. Even when BOHB is measured, the evidence for cutoffs used in DKA diagnosis or exclusion is limited, while its use in gauging severity, treatment progress, and resolution is not fully clear. Lastly, although employing point-of-care meters instead of a laboratory for BOHB measurement brings undoubted benefits, this approach has its own challenges. This article provides a perspective on these topics to complement current recommendations and to suggest how future research may improve its use in the DKA context.
在糖尿病酮症酸中毒(DKA)的诊断和管理中,血液酮体的测量已经成为一种成熟的工具,优于尿液酮体的测量。然而,关于是否、如何以及何时使用该检测,不同的糖尿病指南之间仍然存在很大的差异。虽然最近的指南主要强调血液测量,但仍有一些问题存在。许多实验室仍然使用半定量检测来测量血液酮体,而该检测无法测量主要的酮体——β-羟丁酸(BOHB),这可能会阻碍患者的管理。即使测量了 BOHB,用于 DKA 诊断或排除的切点的证据也很有限,而其用于评估严重程度、治疗进展和缓解的作用也不完全明确。最后,尽管使用即时检测血糖仪而不是实验室来测量 BOHB 带来了无疑的好处,但这种方法也有其自身的挑战。本文就这些问题提供了一些观点,以补充当前的建议,并提出未来的研究如何可能改善其在 DKA 环境中的应用。